RxDoctor Payments Data

Myriam Cruz, MD

Internal Medicine · Lecanto, FLNPI 1053379271

Payments from drug & device makers

$951in general payments, 2019–2025

Across 31 payments — averaging $30.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$251
  • Johnson & Johnson$208
  • E.r. Squibb & Sons, L.L.C.$166
  • Medtronic$72
  • Abbott$43
  • Pfizer$38
  • plus $173 from 9 others

What the payments were for

  • Food & beverage$951100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)11$251
Johnson & Johnson4$208
E.r. Squibb & Sons, L.L.C.2$166
Medtronic1$72
Abbott2$43
Pfizer2$38
PBG Puerto Rico LLC1$24
Corium, LLC1$23
Lilly USA, LLC1$22
Hologic Sales And Service, LLC1$21
Novo Nordisk1$21
Bayer1$17
Amgen1$16
Merck1$16
AstraZeneca1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$951 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$43,229
Medicare patients
141
Services billed
735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$14,686
JardianceEmpagliflozin14$12,680
TrulicityDulaglutide12$11,749
Rosuvastatin Calcium49$587
Gabapentin36$488
Albuterol Sulfate HfaAlbuterol Sulfate14$377
Atorvastatin Calcium27$370
Famotidine36$312
Pantoprazole Sodium25$284
Hydroxyzine Hcl12$283
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$252
Tamsulosin Hcl15$190
Lisinopril44$188
Montelukast Sodium17$164
Levothyroxine Sodium21$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$14,68616 claims
Lilly USA, LLCTrulicity$22$11,74912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lecanto

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →